These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 10578695)

  • 41. Cortisol and hypertension: what was not so apparent about "apparent mineralocorticoid excess".
    Edwards C; Walker B
    J Lab Clin Med; 1993 Dec; 122(6):632-5. PubMed ID: 8245680
    [No Abstract]   [Full Text] [Related]  

  • 42. [Apparent mineralocorticoid syndrome].
    Shimosawa T; Fujita T
    Ryoikibetsu Shokogun Shirizu; 1996; (12):110-3. PubMed ID: 9047420
    [No Abstract]   [Full Text] [Related]  

  • 43. [Hypertension and mineralocorticoids. Usefulness of renin and aldosterone measurements].
    Fardella CE; Montero J; Mosso L
    Rev Med Chil; 1999 May; 127(5):604-10. PubMed ID: 10451632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Rhabdomyolysis and arterial hypertension caused by apparent excess of mineralocorticoids: a case report].
    Sardi A; Geda C; Nerici L; Bertello P
    Ann Ital Med Int; 2002; 17(2):126-9. PubMed ID: 12150047
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Licorice-induced hypermineralocorticoidism.
    Farese RV; Biglieri EG; Shackleton CH; Irony I; Gomez-Fontes R
    N Engl J Med; 1991 Oct; 325(17):1223-7. PubMed ID: 1922210
    [No Abstract]   [Full Text] [Related]  

  • 46. Primary aldosteronism, a common entity? the myth persists.
    Padfield PL
    J Hum Hypertens; 2002 Mar; 16(3):159-62. PubMed ID: 11896504
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Syndromes that Mimic an Excess of Mineralocorticoids.
    Sabbadin C; Armanini D
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):231-5. PubMed ID: 27251484
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Apparent mineralocorticoid excess and the long term treatment of genetic hypertension.
    Razzaghy-Azar M; Yau M; Khattab A; New MI
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):145-150. PubMed ID: 26892095
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Apparent mineralocorticoid excess.
    Wilson RC; Nimkarn S; New MI
    Trends Endocrinol Metab; 2001 Apr; 12(3):104-11. PubMed ID: 11306334
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Licorice-induced hypertension and common variants of genes regulating renal sodium reabsorption.
    Miettinen HE; Piippo K; Hannila-Handelberg T; Paukku K; Hiltunen TP; Gautschi I; Schild L; Kontula K
    Ann Med; 2010 Sep; 42(6):465-74. PubMed ID: 20597806
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nephrocalcinosis and renal cysts associated with apparent mineralocorticoid excess syndrome.
    Moudgil A; Rodich G; Jordan SC; Kamil ES
    Pediatr Nephrol; 2000 Nov; 15(1-2):60-2. PubMed ID: 11095013
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Normokalemic hyperaldosteronism in patients with resistant hypertension.
    Benchetrit S; Bernheim J; Podjarny E
    Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Excess of mineralocorticoids in essential hypertension: clinical-diagnostic approach].
    Cortés P; Fardella C; Oestreicher E; Gac H; Mosso L; Soto J; Foradori A; Claverie X; Ahuad J; Montero J
    Rev Med Chil; 2000 Sep; 128(9):955-61. PubMed ID: 11349499
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Mineralocorticoid-induced hypertension].
    Hensen J; Oelkers W
    Med Klin (Munich); 1997 May; 92(5):273-8. PubMed ID: 9244833
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolic and blood pressure responses to hydrocortisone in the syndrome of apparent mineralocorticoid excess.
    Oberfield SE; Levine LS; Carey RM; Greig F; Ulick S; New MI
    J Clin Endocrinol Metab; 1983 Feb; 56(2):332-9. PubMed ID: 6296185
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [11 beta-Hydroxysteroid dehydrogenase].
    Sun G; Li P; Yang KP; Challis JR
    Sheng Li Ke Xue Jin Zhan; 1998 Oct; 29(4):301-6. PubMed ID: 12501657
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism.
    Sartorato P; Khaldi Y; Lapeyraque AL; Armanini D; Kuhnle U; Salomon R; Caprio M; Viengchareun S; Lombès M; Zennaro MC
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):119-25. PubMed ID: 15134810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Possible pathogenetic role of 11 beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) gene polymorphisms in arterial hypertension].
    Morales MA; Carvajal CA; Ortiz E; Mosso LM; Artigas RA; Owen GI; Fardella CE
    Rev Med Chil; 2008 Jun; 136(6):701-10. PubMed ID: 18769825
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A clinical phenotype mimicking essential hypertension in a newly discovered family with Liddle's syndrome.
    Rossi E; Farnetti E; Nicoli D; Sazzini M; Perazzoli F; Regolisti G; Grasselli C; Santi R; Negro A; Mazzeo V; Mantero F; Luiselli D; Casali B
    Am J Hypertens; 2011 Aug; 24(8):930-5. PubMed ID: 21525970
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The codon 213 of the 11beta-hydroxysteroid dehydrogenase type 2 gene is a hot spot for mutations in apparent mineralocorticoid excess.
    Rogoff D; Smolenicka Z; Bergadá I; Vallejo G; Barontini M; Heinrich JJ; Ferrari P
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4391-3. PubMed ID: 9851783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.